Chronic treatment with the α7nAChR agonist PNU-282987 improved endothelial function and reduced pro-inflammatory cytokines, indicating the role of cholinergic anti-inflammatory signaling in controlling endothelial dysfunction in hypertension [31]. This evidence concerns the gene CHRNA7 and endothelial dysfunction.